Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight (GZBF)

Phase 2 study (GZBF), condition: Obesity. Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling. Enrolment: 300 participants. Status: recruiting. No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.